ライフサイエンスコーパス: subfoveal

1 Twenty percent of incident GA lesions were subfoveal and an additional 18% were within 250 mum of t

2 Subfoveal and average choroidal thickness in the central

3 Both subfoveal and average choroidal thicknesses were associa

4 was 0.95 (74.1 mum) and 0.96 (63.9 mum) for subfoveal and average CT, respectively.

5 ontinuous unilateral anti-VEGF treatment for subfoveal and juxtafoveal neovascular AMD and a minimum

6 ion and choroidal neovascularization that is subfoveal and predominately classic (> 50%).

7 .0001) and external limiting membrane in the subfoveal area (P < .0001) at baseline were the only 2 i

8 roidal thicknesses in the temporal and nasal subfoveal areas were measured using enhanced-depth imagi

9 Subfoveal center point choroidal thickness, mean central

10 Significant difference of subfoveal center point measurement or mean of central mi

11 No significant difference between subfoveal center point measurement/mean of choroidal thi

12 ne scan can represent the entire choroid but subfoveal center point measurements are only indicative

13 Similar pausing behavior was observed in the subfoveal choriocapillaris.

14 wed a normal retina in all patients, but the subfoveal choroid in the hypopigmented region was slight

15 The subfoveal choroid was a mean 23% thicker in the involved

16 In addition, the response of subfoveal choroidal blood flow (-6.2% +/- 3.2%; P = 0.00

17 Subfoveal choroidal blood flow and fundus pulsation ampl

18 All patients had a subfoveal choroidal neovascular membrane with or without

19 adhesion molecule (ICAM)-1 and E-selectin in subfoveal choroidal neovascular membranes (CNVMs) surgic

20 ted macular degeneration secondary to active subfoveal choroidal neovascularisation, with best correc

21 ty-six cases of previously untreated, active subfoveal choroidal neovascularization (CNV) associated

22 Eyes with subfoveal choroidal neovascularization (CNV) lesions had

23 y and Safety of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization (CNV) Secondary t

24 Patients with subfoveal choroidal neovascularization (CNV) secondary t

25 A total of 151 patients with subfoveal choroidal neovascularization (CNV) secondary t

26 During a 4-month period, 29 patients with subfoveal choroidal neovascularization (CNV), who were e

27 sis study evaluated photodynamic therapy for subfoveal choroidal neovascularization caused by presume

28 re collected from 1134 of 1146 patients with subfoveal choroidal neovascularization due to AMD with m

29 reduce the risk of visual loss in eyes with subfoveal choroidal neovascularization from age-related

30 nally, submacular surgery for the removal of subfoveal choroidal neovascularization has promising res

31 rgery or observation is better for eyes with subfoveal choroidal neovascularization in presumed ocula

32 site of the laser photocoagulation scar, and subfoveal choroidal neovascularization is not amenable t

33 n age-related macular degeneration eyes with subfoveal choroidal neovascularization is uniform across

34 us with the first realistic means to address subfoveal choroidal neovascularization lesions from age-

35 ding center of patients with treatment-naive subfoveal choroidal neovascularization receiving intravi

36 hase 2a open-label study in 15 patients with subfoveal choroidal neovascularization secondary to AMD

37 epithelial detachment associated with occult subfoveal choroidal neovascularization with intravitreal

38 y and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization with or without C

39 Therefore, it allows the clinician to treat subfoveal choroidal neovascularization without immediate

40 mise for selected conditions (in particular, subfoveal choroidal neovascularization), the optimal tec

41 of 8.1% for the average person with classic subfoveal choroidal neovascularization, while laser phot

42 teporfin is approved for treatment of occult subfoveal choroidal neovascularization.

43 : Total of 255 treatment-naive patients with subfoveal choroidal neovascularization.

44 (28 eyes) tended to have a greater baseline subfoveal choroidal thickness (239 +/- 12 mum) than the

45 Emmetropic eyes tended to have thicker subfoveal choroidal thickness (381.94 +/- 79.88 mum vs 3

46 led no significant difference in the average subfoveal choroidal thickness (P > 0.05) among systems f

47 onarteritic AION was associated with thinner subfoveal choroidal thickness (P = 0.007) after adjustin

48 N as compared to control eyes showed thinner subfoveal choroidal thickness (P = 0.037) after adjustin

49 01), pseudophakia (P = 0.03), and decreasing subfoveal choroidal thickness (r = -0.27; P = 0.003).

50 Subfoveal choroidal thickness (SCT) was measured using t

51 Subfoveal choroidal thickness (SFCT) and choroidal thick

52 Subfoveal choroidal thickness (SFCT) in young-preterm in

53 ce, two experienced OCT readers measured the subfoveal choroidal thickness (SFCT) of the horizontal a

54 f the LLQ scores and age, RIT, AMD severity, subfoveal choroidal thickness [SFCT], phakic status, and

55 The decrease in subfoveal choroidal thickness after anti-VEGF treatment

56 A negative correlation between subfoveal choroidal thickness and age was detected in al

57 Strong correlations between subfoveal choroidal thickness and axial length and myopi

58 erence tomography scans were used to measure subfoveal choroidal thickness and central macular thickn

59 erence tomography scans were used to measure subfoveal choroidal thickness and central macular thickn

60 Mean subfoveal choroidal thickness and mean subfoveal medium

61 The subfoveal choroidal thickness and the subfoveal medium c

62 inal atrophy, central retinal thickness, and subfoveal choroidal thickness are likely to be valuable

63 After 3 monthly anti-VEGF treatments, subfoveal choroidal thickness decreased significantly (2

64 Subfoveal choroidal thickness decreased significantly in

65 Subfoveal choroidal thickness decreased with age, wherea

66 The subfoveal choroidal thickness did not vary between ethni

67 In this study, eyes with a thicker baseline subfoveal choroidal thickness had better short-term anat

68 rols (331 mum +/- 24; mean +/- 95% CI), mean subfoveal choroidal thickness in eyes of patients with P

69 The estimation of the variation in the subfoveal choroidal thickness in relationship to the axi

70 Mean subfoveal choroidal thickness in the bullous CSC group (

71 the most significant factor associated with subfoveal choroidal thickness in the entire group, follo

72 f the central macular subfield and 35 mum in subfoveal choroidal thickness is necessary to detect tru

73 Baseline subfoveal choroidal thickness may help predict which pat

74 Subfoveal choroidal thickness measured with EDI-OCT was

75 We evaluated subfoveal choroidal thickness measured with two differen

76 Manual subfoveal choroidal thickness measurements were made by

77 Subfoveal choroidal thickness obtained with two differen

78 In the entire group the mean subfoveal choroidal thickness of those without loculated

79 sion was used to evaluate the association of subfoveal choroidal thickness or average choroidal thick

80 f the subfoveal fluid and a reduction of the subfoveal choroidal thickness to 271 mum after a 3 month

81 t was used to assess the correlation between subfoveal choroidal thickness values determined by the t

82 Mean subfoveal choroidal thickness was 156 mum (147, 42-362 m

83 Mean (SD) subfoveal choroidal thickness was 332 (90) mum (right ey

84 The intrasession CR of subfoveal choroidal thickness was 34.7 mum (95% CI 33.7-

85 Mean subfoveal choroidal thickness was 345.67 +/- 81.80 mum a

86 Mean subfoveal choroidal thickness was 381 mum (standard devi

87 ween the perivascular stromal tissue and the subfoveal choroidal thickness was 66% in the study eye a

88 te analyses revealed that a greater baseline subfoveal choroidal thickness was associated with a bett

89 In multivariate analysis, thinner subfoveal choroidal thickness was associated with the di

90 Subfoveal choroidal thickness was greater in patients wi

91 Subfoveal choroidal thickness was measured as the distan

92 pectral-domain optical coherence tomography; subfoveal choroidal thickness was measured manually usin

93 Subfoveal choroidal thickness was measured using EDI-OCT

94 Baseline subfoveal choroidal thickness was not significantly diff

95 A significant reduction in subfoveal choroidal thickness was noted after anti-VEGF

96 that choroidal melanocytosis shows increased subfoveal choroidal thickness with an apparent increase

97 In the myopic group, the variation in the subfoveal choroidal thickness with the myopic refractive

98 presence of RPD, AMD severity, and decreased subfoveal choroidal thickness.

99 using a DRI SS OCT, and line measurements of subfoveal choroidal thicknesses (SFCT) were also perform

100 velopment and validation datasets, with mean subfoveal choroidal thicknesses of 307 and 293 microm, r

101 Based on average and subfoveal choroidal thicknesses, the choroid of eyes wit

102 Subfoveal ChT was 315 +/- 106 mum (mean +/- SD), negativ

103 proximately 1500 mum inferior, compared with subfoveal ChT.

104 Older age, subfoveal CNV location, and larger baseline lesion size

105 Autorefraction in patients with subfoveal CNV may be a satisfactory alternative to manif

106 zumab, Study of Ranibizumab in Patients with Subfoveal CNV Secondary to AMD, Extension Study to Evalu

107 Eleven subjects with occult subfoveal CNVM due to AMD were assessed in a masked fash

108 In subfoveal CNVMs from patients with AMD, there is increas

109 localization of ICAM-1 and E-selectin in 10 subfoveal CNVMs was determined by immunohistochemistry.

110 eam radiation therapy in seven fractions for subfoveal CNVMs were found to have recurrent or persiste

111 Subfoveal CSJ was visualized in 96% of young-preterm inf

112 Regression analysis suggested that subfoveal CT decreased by 11.9 mum for each decade of li

113 A difference of 74.1 mum in subfoveal CT or 63.9 mum in average CT may be necessary

114 The mean subfoveal CT was 118 mum (+/- 68 mum) and correlated neg

115 Subfoveal CT was 297.8 +/- 82.2 mum, which did not diffe

116 The subfoveal CT was inversely correlated with the logMAR vi

117 Subfoveal CT was measured using 3 different posterior bo

118 of myopia, whereas visual acuity depends on subfoveal CT.

119 ual acuity decreases in line with decreasing subfoveal CT.

120 Before surgery, a subfoveal detachment (SD) corresponding to the yellow de

121 Subfoveal detachments do not affect visual outcome and s

122 Subfoveal detachments secondary to idiopathic ERM were o

123 in an uncomplicated pregnancy with extensive subfoveal exudates and severe permanent visual loss.

124 he subretinal fluid and the disappearance of subfoveal exudates.

125 ase and that there is a subclinical stage of subfoveal exudation ('preoccult') for patients with age-

126 in age-related macular degeneration without subfoveal fibrosis at first presentation who were treate

127 Subfoveal fibrosis at the conclusion follow-up of 24 mon

128 The hazard ratio of any subfoveal fibrosis developing in eyes with predominantly

129 The development of subfoveal fibrosis in neovascular age-related macular de

130 cause of severe atrophic macular changes and subfoveal fibrosis, no improvement of visual acuity was

131 NSD was defined as subfoveal fluid accumulation under detached retina with

132 Transient subfoveal fluid accumulation was noted in all these pati

133 EDI-OCT showed resolution of the subfoveal fluid and a reduction of the subfoveal choroid

134 eoschisis and foveal detachment in which the subfoveal fluid had spontaneously resolved.

135 ome healthy full-term infants have bilateral subfoveal fluid not obvious on dilated retinal examinati

136 Six (15%) of the 39 infants had bilateral subfoveal fluid on SD OCT not seen by indirect ophthalmo

137 ts were mild foveal thickening and prominent subfoveal fluid, and those in sham-treated patients were

138 rom 20/20 to 20/200 after the development of subfoveal fluid.

139 t epithelium (RPE) atrophy/absence in 22.9%, subfoveal geographic atrophy in 2.5%, and fluid in or un

140 of the subretinal tissue complex on OCT, and subfoveal geographic atrophy or scar on FP/FA had the wo

141 ysiology of ocular diseases characterized by subfoveal hypoxia and VEGF upregulation, such as age-rel

142 nt in 213 of 515 (41%) gradable eyes and was subfoveal in 85 eyes (17%).

143 The maximal choroidal thickness was subfoveal in 9 of 41 eyes (22%), focal choroidal thinnin

144 d AAV.REP1 (0.6-1.0x10(10) genome particles, subfoveal injection).

145 All patients had subfoveal involvement with choroidal melanocytosis.

146 subfoveal total choroidal thickness and mean subfoveal large choroidal vessel layer thickness were si

147 namic therapy has also proved beneficial for subfoveal lesions secondary to high myopia.

148 reatment-naive neovascular AMD patients with subfoveal lesions were treated and examined monthly for

149 ocular histoplasmosis, in particular that of subfoveal localization.

150 pic eyes was thickest temporally compared to subfoveal location in emmetropic subjects (thickest poin

151 The subfoveal choroidal thickness and the subfoveal medium choroidal vessel layer and choriocapill

152 Mean subfoveal choroidal thickness and mean subfoveal medium choroidal vessel layer and choriocapill

153 Average, subfoveal, nasal, and temporal choroidal thicknesses wer

154 on an as-needed Basis (PRN) in patients with subfoveal neOvasculaR age-related macular degeneration (

155 on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration).

156 ty eyes of 120 patients with treatment-naive subfoveal neovascular AMD participated in this study at

157 0 years were eligible if they presented with subfoveal neovascular AMD, with best-corrected visual ac

158 eyes with diabetic macular edema (DME) with subfoveal neuroretinal detachment (SND+) vs DME without

159 In 3 patients OCT revealed subfoveal neuroretinal elevation, often asymptomatic, al

160 the detailed clinical findings of bilateral subfoveal neurosensory retinal detachment associated wit

161 s may prompt the ophthalmologist to consider subfoveal neurosensory retinal detachment.

162 ived oral MEK inhibitors developed bilateral subfoveal neurosensory retinal detachment.

163 We report on a series of bilateral subfoveal neurosensory retinal detachments in patients w

164 on, although a large minority of lesions are subfoveal or multifocal at initial detection.

165 atients (4 eyes) had "severe" injuries, with subfoveal outer retinal architecture loss and overlying

166 ever, there was no significant difference in subfoveal (P = .675) or average choroidal thickness (P =

167 of eyes varied substantially by the type of subfoveal pathology on FP and FA: 70.6 for no pathology;

168 th age-related macular degeneration who have subfoveal predominately classic choroidal neovasculariza

169 in photodynamic therapy for the treatment of subfoveal, predominately classic, choroidal neovasculari

170 The CT was measured at the subfoveal region in a horizontal fashion, 3 mm temporal

171 Similar results were observed for the subfoveal region.

172 cancer, with bilateral uveitis and bilateral subfoveal retinal detachment.

173 Fundus examination showed subfoveal severe exudation with a posterior pole serous

174 al fluid, pigment epithelial detachment, and subfoveal thickening.

175 The subfoveal thickness difference was -4.1 mum on horizonta

176 of subretinal thickening (P = .003), intact subfoveal third hyperreflective band (P = .006), and int

177 Mean subfoveal total choroidal thickness and mean subfoveal l

178 yes where the SCL was not visible, mean [SD] subfoveal VCT was 222.3 [101.5] mum and StCT and TCT wer

179 In eyes where the SCL was visible, mean [SD] subfoveal VCT, StCT, and TCT were 221.9 [83.1] mum, 257.

180 Patients aged >/=50 years with subfoveal wet age-related macular degeneration (AMD) who